Browse
Submit Data
Databases
API
Help

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with Metastatic Colorectal Carcinoma Receiving Panitumumab

ABSTRACT: Primary objectives: To compare the patient rated efficacy of preemptive basic skin treatment with or without doxycycline on the occurrence and grade of panitumumab induced skin toxicities and resulting in the end of study treatment Primary endpoints: Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient’s allocating point 6 through 10 on a visual analogue scale)

DISEASE(S): Skin Toxicity Treatment In Patients With Wild-type Kras Metastatic Colorectal Cancer (mcrc) Treated With Panitumumab• In First-line In Combination With Folfox• In Second-line In Combination Wit...,Colorectal Cancer Metastatic,Skin Toxicity Treatment In Patients With Wild-type Kras Metastatic Colorectal Cancer (mcrc) Treated With Panitumumab • In First-line In Combination With Folfox • In Second-line In Combination With Folfiri For Patients Who Have Received First-line Fluoropyrimidine-based Chemotherapy (excluding Irinotecan) • As Monotherapy After Failure Of Fluoropyrimidine-, Oxaliplatin-, And Irinotecan-containing Chemotherapy Regimens

PROVIDER: 2527993 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

Project description:80 - 90 % of the patients treated with anti-EGFR antibodies (panitumumab or cetuximab) experience skin toxicity, mostly acne like skin rash. A standardized treatment of skin rash is neither established as standard arm for clinical trials nor as guideline for the treatment of skin toxicity in clinical practice. While an improvement of QoL has been demonstrated for panitumumab and cetuximab in comparison to best supportive care the data basis for patient related outcomes regarding skin toxicity deriving from randomized trials is still small. Recent surveys among German oncologist revealed that physicians are reluctant to use oral antibiotics as preemptive treatment . Only 19 out of 110 oncologists stated that they are thinking about using preemptive treatment in patients with acne-like skin rash. Thus, in the present trial two main questions will be addressed: (i) Can preemptive treatment with oral doxycycline be replaced by a sequential skin treatment strategy (i.e. local treatment with erythromycin followed by doxycycline in case of inefficacy = development of acne) without compromising treatment efficacy of skin toxicity treatment? (ii) Comparison of general and skin related QoL between both treatment arms.

| 2130638 | ecrin-mdr-crc

1c159679-f652-42db-af78-bfcaede9895b - samples

Project description:Dataset contains fastq files of tumor transcriptomes of 12 pituitary neuroendocrine tumors. Patients with and without somatostatin analogue treatment before tumor surgery can be compared. Sequencing was performed on MGISEQ-2000.

| EGAD00001006446 | EGA

Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream

Project description:The aim of this Phase 2, two-arm, randomized, double blind placebo controlled study is to evaluate the efficacy of combination therapy of doxycycline and Vitamin K1 compared to doxycycline plus placebo for the prevention of acne-like skin rash in mCRC patients receiving first line cetuximab treatment.

| 2106044 | ecrin-mdr-crc

RNA-seq of CCDC137-APOBEC1 expressing HCCLM3 cells [APOBEC1-seq]

Project description:We established GFP/CCDC137-APOBEC1 transfected HCCLM3 cells.Then doxycycline was added to induce the expression of GFP/CCDC137-APOBEC1.We then performed gene expression profiling analysis using RNA obtained from GFP/CCDC137-APOBEC1 overexpressing HCCLM3 cells with or without doxycycline treatment.

2023-07-01 | GSE217914 | GEO

Whole culture RNA-sequencing of transient DUX4-expressed human embryonic stem cells

Project description:Doxycycline-induced and control DUX4-TetOn human embryonic stem cells (hESCs) were collected immediately, 24 h, and 48 h after 15 min, 30 min of doxycycline, or without doxycycline treatment. Moreover, doxycycline-induced hESCs were sorted by FACS with an antibody against NaPi2b (SLC34A2) at 6 h after induction and collected after a further 6 h of culture. These cells were compared with unsorted cells, cells without doxycycline treatment, and H9 primed/naive hESCs as controls.

2022-12-31 | E-MTAB-10569 | biostudies-arrayexpress

Gene expression from human iPSC derived cortical neurons

Project description:Gene expression from icas9 human iPSC derived cortical neurons treated with and without doxycycline

| EGAS00001004782 | EGA

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment

Project description:Up to 60% of patients with metastatic colorectal cancer can be treated with one of monoclonal antibodies targeted against epidermal growth factor receptor (EGFR). This treatment is associated with a specific spectrum of toxicity: acne-like rash from limited up to erythema, often with severe pruritus, sometimes combined with other types of skin toxicities (hair and nail changes). Previously in STEPP study investigators shown that pre-emptive treatment with oral doxycycline (200 mg daily), topical steroids and sun blockers reduces the number of more severe skin side effects of panitumumab. The study is designed to described the profile of skin toxicity of EGFR blocking drugs combined with low-dose doxycycline (100 mg daily) used in the pre-emptive manner.

| 2108692 | ecrin-mdr-crc

Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)

Project description:Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.

| 2267065 | ecrin-mdr-crc

CEA_SGF:E00010#bcr-abl

Project description:Chronic myelogenous leukemia (CML) is a malignant disease of the hematopoietic stem cell, characterized by the expression of the Bcr-Abl oncogene by leukemic cells. In order to analyze the molecular pathways modulated by Bcr-Abl, we have previously generated an inducible model of Bcr-Abl expression in the murine Ba/F3 cell line based on the Tet-OFF system. In the present study, through a microarray approach applied to cells grown with (Bcr-Abl-expression OFF) or without (Bcr-Abl-expression ON) doxycycline, a tetracycline analogue, we analyzed the gene expression variations upon Bcr-Abl expression. Keywords: repeat sample

2005-05-01 | GSE1429 | GEO

CEA_SGF:E00010#bcr-abl

2005-05-01 | E-GEOD-1429 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data